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ABSTRACT 
Objectives: To estimate the incidence of occult uterine malignancies during laparoscopic supracervical hysterectomy (LSH). 
Material and methods: Retrospective cohort study based on archival data (2010–2016) of the Department of Gynecology 
and Oncology, Jagiellonian University. 
Results: Medical records of 696 women, who underwent LSH were analyzed. Two occult sarcomas (2/696; 0.29%, 0.003, 
95% CI: 0.001 to 0.01), including one case of low-grade endometrial stromal sarcoma (ESS) with co-occurring atypical 
endometrial hyperplasia (AH) and one case of high-grade ESS were found postoperatively. One case of invasive primary 
fallopian tube cancer (1/696; 0.14%, 0.001, 95% CI: 0.00 to 0.008) and additional three cases of AH (3/696; 0.57%, 0.004, 
95% CI: 0.001 to 0.013) were also identified. No case of EC was documented. One hundred sixty nine (24.3%) women of 
696 had an endometrial sampling prior LSH including these with ESS. We did not observe worsening of the prognosis and 
all patients with confirmed malignancy are still alive and free from recurrence in 2–5 years of observations. 
Conclusions: Most commonly the occult malignancy would have not been recognized if the surgery had not been conducted. 
When appropriate diagnostics is conducted, rare incidents of malignant tissue morcellation should not be considered as 
a professional misconduct but as a possible adverse event. Patients should be informed about the risk of malignancy ac-
cording to available estimations and that endometrial sampling cannot eliminate such a risk. A consensus regarding safe 
indications, required diagnostics, and justifiability of mandatory use of contained morcellation for LSH should be developed.
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INTRODUCTION 
Laparoscopic supracervical hysterectomy (LSH) is an al-
ternative to total laparoscopic hysterectomy (TLH) in the 
treatment of benign uterine pathologies. LSH is often pre-
ferred due to (i) lower invasiveness, easier and faster surgical 
technique, (ii) sparing the uterus suspension (lower risk of 
iatrogenic prolapse), (iii) lower risk of other complications 
(ureteral and bladder damage, infections), (iv) faster recov-
ery, and (v) better patient-reported quality-of-life and sexual 
function compared to TLH [1]. 
Power morcellation plays a key role in uterine corpus 
extraction through small incisions within abdominal wall 
[2, 3]. During the management of mild uterine disease, 
there is a risk of missing occult malignancy. In such cases, 
the patient does not receive proper primary treatment. 
Moreover, the morcellation of uterine bodies containing 
occult malignant tumors may contribute to spreading 
malignancies [4, 5]. The FDA’s April 2014 statement [6, 
7], published following the incidental morcellation of the 
uterine leiomyosarcoma, efficiently supplanted minimally 
invasive procedures associated with use of power mor-
cellation, including LSH, in the United States (US) [8, 9]. 
In other countries, the power morcellation and LSH are 
commonly performed [10].
The majority of previous studies was related to sarcoma 
and leiomyosarcoma, and was not focused on any particular 
procedure, or on other uterine malignancy, such as the 
most common endometrial cancer (EC), which may be also 
a subject of non-intentioned power morcellation. Reports 
from various centers around the world are strictly necessary 
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to estimate the real risk justifying the patients’ request for 
these procedures or their refusal. 
The main objective of the study was to estimate the in-
cidence of occult uterine malignancies during LSH. Planned 
secondary aims were: (i) assessment of prognostic factors of 
occult malignancy based on specific patient characteristic 
and (ii) impact of occult malignancy on overall progno-
sis. Finally, we showed our results together with results from 
available literature.
MATERIAL AND METHODS
Study design 
Retrospective cohort study was performed with the use of 
archival data of the Department of Gynecology and Oncology 
of the Jagiellonian University. The local Bioethics Committee 
approved the research (No 122.6120.91.217). The search covers 
procedures performed between 2010 and 2016.
Patient data was obtained both from electronic data-
bases and traditional documentation using medical records 
encoded according to the International Statistical Classifi-
cation of Diseases and Related Health Problems (ICD-10) 
and the International Classification of Medical Procedures 
(ICD-9). The criterion of inclusion was the qualification to 
LSH procedure with or without salpingo-oophorectomy. The 
exclusion criteria were: conversion to laparotomy and con-
version to total laparoscopic hysterectomy. Patient demo-
graphic and medical data, reported symptoms, ultrasound 
results, specific histopathological findings and eventual 
tumor characteristics were obtained from medical records, 
ultrasound and histopathological results. The incidence 
of occult malignancies in histopathology results after LSH 
was counted. The frequency of preoperative endometrial 
histological verification was evaluated. 
Pre-surgical assessment 
Women were examined by specialists in obstetrics and 
gynecology or gynecological oncology and then qualified 
for surgical treatment. More than 15 specialists were in-
volved in patients’ evaluation within the research period. The 
gynecological examination with speculoscopy and trans-
vaginal ultrasound was followed by detailed counseling. 
A cervical PAP test, not older than 1 year, was required before 
surgery, and colposcopy if needed. If other surgeries (ie. 
hysteroscopic myomectomy) were considered, sonohyster-
ography with 3D imaging was available as diagnostic tools 
[11]. All women provided written informed consent to the 
proposed treatment. 
The qualification criteria for LSH were not strictly stand-
ardized and reflected individual patient’s preference and 
doctor’s suggestions. The lack of local guidelines for the 
surgical treatment of pathologies suspected of myoma or 
other benign conditions justified the management based on 
the best knowledge and experience of a physician. Doctors 
performed individual assessment of potential malignancy 
and the justification of endometrial histological verification. 
Symptomatic patients reporting abnormal uterine bleed-
ing, abdominal pain, compression symptoms or pelvic 
organ prolapse were intended for surgery. In individually 
selected cases asymptomatic patients were also directed 
to surgery, considering the results of gynecological exami-
nation and imaging studies, and patients’ preference. In 
the case of abnormal uterine bleeding and/or abnormal 
ultrasound image of the endometrium, patients were first 
referred to histological verification of the endometrium 
(hysteroscopy, Pipelle or D&C). 
Surgery
Procedures were performed by gynecologists of varied 
clinical experience and different levels of training in lapa-
roscopy. The surgical technique was consistent through-
out the study period, with the exception of management 
concerning fallopian tubes. A power morcellator (Rotocut 
G1 and G2 15mm; Karl Storz, Tuttlingen, Germany) was 
used to shred and remove cut off uterine corps. Methods of 
contained power morcellation were not used in the study 
period [12]. Collected tissue material was fixed in 10% for-
malin and sent for histopathological examination. In case of 
macroscopic suspicion of malignant lesion, intraoperative 
histological verification was available.
Histological examination
The tissue specimens were evaluated by a specialist pa-
thologist in a tertiary center of pathomorphology (Depart-
ment of Pathomorphology, Jagiellonian University, Krakow, 
Poland). In case of diagnostic doubt, experts in the field 
consulted specimens in order to ensure the highest reli-
ability of histological diagnosis.
Statistical analysis
Methods of descriptive statistics were used to character-
ize demographic and clinical data in the study population. 
Continuous variables were characterized using mean and 
standard deviations for normal distribution and median, 
quartile and lower quartiles in all other cases. Maximum and 
minimum values of variables were also given. Categorical 
variables were depicted as the number of cases and the 
percentage. The Wilson method was used for calculation 
of 95% confidence intervals (CIs). Statistical analysis was 
performed using the IBM SPSS v. 23.
RESULTS
Patients
During the time period covered by the study, 
735 women were qualified to LSH. We excluded 39 (5.3%) 
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patients in whom surgery ended in conversion to oth-
er procedures (laparotomy and TLH). Medical records 
of 696 women, who underwent LSH, with or without 
salpingo-oophorectomy or salpingectomy, were ana-
lyzed. The majority of women (623/696; 89.5%) were at 
premenopausal age and 73/696 (10.5%) were postmeno-
pausal. Women who gave birth at least once (614/696) 
accounted for 88.2% of the study population and nul-
liparous (82/696) to 11.8%. Detailed characteristics of the 
study population like median age, BMI, gravidity, parity 
are shown in Table 1. 
None of the quantitative variables had a normal dis-
tribution (in the Kolmogorov-Smirnov test p < 0.01). Me-
dian age was 47 years and median body mass index (BMI) 
was 25 (lower-upper quartile: 22.85–28.04). Median gravidity 
was 2 (range 1–2) and median parity was also 2 (lower-upper 
quartile: 1–2). Of ultrasound parameters (Tab. 2), median en-
dometrial thickness was 6 mm (lower-upper quartile: 4–10) 
and median biggest fibroid diameter was 40 mm (lower-up-
per quartile: 26–52). 
With regard to the parameters associated with surgery 
(Tab. 3), median surgical tissue specimen weight was 140 g 
(lower-upper quartile: 83–215). Median pre-operative hemo-
globin level was 13g/dl (lower-upper quartile: 11.95–13.7). 
Median duration of surgery from the start to the end of 
general anesthesia was 95 minutes (lower-upper quartile: 
80–115). Fifteen patients had previously suffered from ma-
lignancy (breast cancer in 12 cases, thyroid cancer, hepatic 
cancer and colon cancer in 1 each).
One hundred sixty nine (24.3%) women of 696 had 
an endometrial sampling before LSH. Out of these women, 
159 underwent dilation and curettage (D&C), 5 had an as-
piration biopsy (Pipelle), and 5 had hysteroscopy.
The main indication for surgery (Tab. 4), in 629 out of 
696 patients (90.4%), was symptomatic uterine fibroids, 
subsequently adenomyosis in 27 patients (3.9%) and 
uterine prolapse in 35 patients (5.0%), appearing sepa-
rately or in combination. In case of uterine prolapse, the 
procedure was combined with the suspension of the 
cervical stump. The most frequently reported symptoms 
in the study population were heavy menstrual bleed-
ing (440 patients, 63.2%), irregular menstrual bleeding 
(77 patients, 11.0%), pelvic pain (102 patients, 14.7%), 
postmenopausal bleeding (6 patients, 0.9%), appearing 
separately or in combination. Less frequently reported 
symptoms were discomfort due to uterine prolapse, 
compression symptoms and urinary incontinence 
(71 patients, 10.2%). Ninety-one (13.7%) patients did 
not report any symptoms, among them patients with 
genetic risk of breast and ovarian cancer, and those 
who wished to undergo surgery due to asymptomatic 
fibroids. 
Table 1. Population characteristics
Variable Mean - 95% CI + 95% CI SD Min. Max. Median Lower quartile
Upper 
quartile
Age 47.50 47.07 47.93 5.77 26.00 80.00 47.00 44.00 51.00
BMI 25.88 25.53 26.24 4.64 15.88 66.66 25.00 22.85 28.04
Gravidity 1.86 1.78 1.94 1.09 0.00 7.00 2.00 1.00 2.00
Parity 1.72 1.64 1.79 0.99 0.00 7.00 2.00 1.00 2.00
Hemoglobin 12.66 12.53 12.79 1.49 6.70 16.30 13.00 11.95 13.70
Table 2. Endometrium thickness and diameter of presumed myomas
Variable Mean -  95% CI + 95% CI SD Min. Max. Median Lower quartile
Upper 
quartile
Fibroid biggest diameter* 38.47 35.95 40.98 22.92 0.00 100.00 40.00 26.00 52.00
Endometrial thickness** 7.31 6.80 7.81 3.82 2.00 24.00 6.00 4.00 10.00
* N — 629; ** N — 696
Table 3. Surgical parameters
Variable Mean - 95% CI + 95% CI SD Min. Max. Median Lower quartile
Upper 
quartile
Tissue weight 173.16 159.17 187.16 133.67 20.00 936.00 140.00 83.00 215.00
Duration of surgery* 99.96 97.83 102.08 28.28 35.00 245.00 95.00 80.00 115.00
* from the start to the end general anesthesia 
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Adverse events and complications 
One intra-operative complication caused by morcel-
lator was noted (the fragmentation of epiploic appendix). 
Thirteen (1.9%) of out 696 patients required revision of the 
surgical field due to hemorrhage into the abdominal cavity 
in post-operative course. There was one morcellator failure 
that resulted in conversion to laparotomy and the patient 
was excluded (Tab. 5). 
Prevalence of malignancy and atypical 
hyperplasia 
In total, two sarcomas (2/696; 0,29%, 0.003, 95% CI: 
0.001 to 0.01), including one case of low-grade endometrial 
stromal sarcoma (ESS) with co-occurring atypical endome-
trial hyperplasia (AH) and one case of high-grade ESS were 
found postoperatively (Tab. 6). Interestingly, only the first 
case concerns the patient with coexisting symptomatic fi-
broid, in the second case the indication for LSH was bleeding 
disorder (heavy menstrual bleeding). One case of invasive 
primary fallopian tube cancer (1/696; 0.14%, 0.001, 95% 
CI: 0.00 to 0.008) and additional three cases of AH (3/696; 
0.57 %, 0.004, 95% CI: 0.001 to 0.013) were also identified. 
No case of EC was documented. The patient diagnosed 
with low-grade sarcoma stromale underwent dilation and 
curettage (D&C) 6 months prior to surgery and the patient 
diagnosed with high-grade endometrial stromal sarcoma 
had an endometrial aspiration biopsy 3 months before the 
surgery. Both results showed no endometrial pathology. 
The patient diagnosed with invasive primary fallopian tube 
cancer did not have endometrium sampled in preoperative 
assessment. Two out of three patients with AH underwent 
D&C and the results were unsuspected (hyperplasia without 
atypia in one case). All three patients diagnosed with malig-
nancy were further directed to second-look laparotomy in 
Table 4. Lesions and symptoms associated with indications for surgery
Lesions/Symptoms N (%)
Uterine fibroids 629 (90.37)
Adenomyosis 27 (3.88)
Uterine prolapse 35 (5.03)
Heavy menstrual bleeding 440 (63.22)
Irregular menstrual bleeding 77 (11.06)
Pelvic pain 102 (14.66)
Postmenopausal bleeding 6 (0.86)
Discomfort due to uterine prolapse, compression symptoms, urinary 
Incontinence 71 (10.2)
No symptoms 91 (13.07)
Table 5. Intraoperative and early postoperative complications
Complication N (%)
Fragmentation of epiploic appendix 1 (0.14)
Revision of the surgical field due to hemorrhage 13 (1.87)
Morcellator failure 1 (0.14)
Table 6. Occult malignant and precancerous conditions in specimens from LSH
Histology N (%)
Occult malignancy
Low-grade ESS + AH 
High-grade ESS
Invasive primary fallopian tube cancer
1 (0.14) 
1 (0.14)
1 (0.14)
Precancerous condition
AH 3 (0.43)
Other
Endometrial hyperplasia without atypia
Atypical myoma
16 (2.3)
4 (0.6)
LSH — Laparoscopic supracervical hysterectomy; ESS — Endometrial stromal sarcoma; AH — Atypical endometrial hyperplasia
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order to ensure a radical surgical treatment. No dissemina-
tion, or other abnormalities in the abdominal cavity were ob-
served in patients who had previously undergone LSH with 
morcellation of uterine malignancy during a second-look 
operation. 
Impact on prognosis 
Due to the small number of occult malignant tumors, it 
was not possible to accomplish additional study objectives, 
i.e. assessment of prognostic factors of occult malignancy 
and impact of occult malignancy on overall prognosis. How-
ever, we did not observe worsening of the prognosis and 
all patients with confirmed malignancy are still alive and 
free from recurrence in 2–5 years of observations. Detailed 
characteristics are shown in Table 7.
Endometrial hyperplasia without atypia and 
atypical myomas
Some patients were also diagnosed with other spe-
cific lesions: endometrial hyperplasia without atypia 
(16/696 cases, 2.3%), leiomyoma cellulare (10/696 pa-
tients, 1.4%), leiomyoma partim cellulare (30/696 pa-
tients, 4.3%), atypical myoma (4/696 patients, 0.6%), leio-
myoma bizzare (2/696 patients, 0.29%) and adenomyoma 
(10/696 patients, 1.4%). 
DISCUSSION
We found three occult malignancies in the cohort of pa-
tients who underwent LSH: two uterine sarcomas (low-grade 
and high-grade ESS) and one case of invasive primary fal-
lopian tube cancer. Both patients with ESS underwent en-
dometrial sampling before surgery. Three other patients 
had AH, and two of them underwent endometrial sampling, 
which did not reveal atypical cells. 
The study may be vital in modifying the everyday coun-
seling dedicated to patients, who are candidates for LSH, 
especially regarding informed consent, risk of malignancy, 
as well as endometrial sampling before surgery. Moreover, 
the study results that may be unique regarding ethnicity 
(Caucasians) may support further meta-analyses and local 
guidelines. Despite potential differences between Polish 
population and available data form other populations, our 
study results showed that the presence of undiagnosed 
uterine malignancy in morcellated specimens is similar 
(1/348 vs. 1/350) as reported by FDA based on other studies 
focusing on all laparoscopic procedures with power morcel-
lation [13]. However, it should be noted that FDA focused 
on uterine sarcomas in women undergoing surgery due to 
presumed myomas.
Findings from our study indicates that pre-surgical en-
dometrial sampling does not eliminate the occurrence of 
undetected uterine malignant tumor and precancerous 
conditions (AH), even in cases considered as detectable in 
appropriate evaluation, including ultrasound and endo-
metrial sampling [14]. The fact is that 25% of the patients 
underwent endometrial sampling, however the two uterine 
malignancies were found after negative results of endome-
trial sampling. Thus, patients should be informed about both 
aspects, i.e. that the risk of morcellation of malignant tissue 
is present, and that the routine endometrial diagnostic (ul-
trasound, endometrial sampling) does not exclude the risk of 
malignancy. It is an open question whether to recommend 
obligatory pre-operative endometrial sampling. Accord-
ing to recent ESMO-ESGO-ESTRO consensus there are no 
Table 7. Characteristics of women diagnosed with malignant or premalignant conditions in specimens from LSH
Date Age BMI HP Endometrial sampling Menopausal st. Symptoms Second treatment ADD. treatment
30.05.16 53 28.28 low-grade ESS D&C pre- HMB/IMB
Laparotomy. BSO. 
Removal of cervix.   
Omentectomy. PLND.  
0
28.09.15 42 22.04 high-grade ESS pipelle pre- HMB
Laparotomy. BSO.  
Removal of the 
cervix.  Omentectomy. 
Appendectomy.  PLND. 
0
02.10.12 56 21.88
Adenocarcinoma 
serosum of 
fallopian tube 
0 post- POPQ 3 Laparotomy. Removal of the cervix.  PLND.  Taxol/Carboplatin 
19.09.13 53 27.12 AH D&C post- HMB Laparotomy. BSO.  Removal of the cervix.  0
07.11.16 55 23.05 AH 0 post- POPQ 3 Laparoscopy.  Removal of the cervix.  0
10.09.15 52 25.91 AH D&C pre- HMB Lack of data –
ESS — Endometrial stromal sarcoma; AH — Atypical emdometrial hyperplasia; HMB — Heavy, menstrual bleeding; IMB — Intermenstrual bleeding; BSO — Bilateral 
salphingoophorectomy; PLND — Plevic lymph node dissection
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indications to perform the screening of EC in asymptomatic 
patients [15]. On the other hand, the National Institute for 
Health and Clinical Excellence (NICE) recommends screen-
ing at cancer risk level of 3% [16]. Most women subjected 
to LSH as definitive treatment suffered from myomas and 
abnormal uterine bleeding (AUB), and most of them were 
before menopause. In premenopausal women undergoing 
D&C due to AUB in our center the incidence of EC is 0.9% [17]. 
It seems, that performing endometrial sampling does not 
seem to be pivotal in all patients destined to undergo LSH. 
However, the negative result of sampling may be helpful 
to prevent legal litigation. On the other hand prophylactic 
endometrial sampling seems scientifically unjustifiable due 
to the low malignancy prevalence, and should not be con-
sidered as obligatory screening before LSH. 
In situations where there are specific, yet not strong 
advantages of LSH in comparison to total laparoscopic or 
vaginal hysterectomy, the risk and benefits of LSH should 
be weighed. It is reasonable that LSH should be proposed 
as an alternative for other minimally invasive procedures 
without morcellation, i.e. TLH or vaginal hysterectomy (VH), 
only in patients with very low risk of malignancy.
The weak points of our study are similar to those of the 
majority of the studies in the field, i.e. retrospective design, 
specifics of the tertiary and teaching center and population 
treated [18]. Although a single specific procedure (LSH) was 
analyzed, results seem to be generalizable, especially when 
regarding this procedure in the context of local tendencies 
of qualification given particular symptoms, ultrasound re-
sults and size of uteri. Taking into account the above, the 
true incidence of occult malignancies in all patients who 
may be considered as candidates for LSH may not coincide 
with the obtained calculations. The majority of women were 
operated on due to symptomatic myomas and in the study 
period LSH was proposed as main option when malignan-
cies were potentially excluded (endometrial sampling) or 
not suspected on ultrasound, gynecological examination 
and Pap smear. 
The strengths of the research in the context of the pre-
sented results are: (i) good quality electronic database of 
prospectively included all consecutive patients who un-
derwent LSH; (ii) results reflecting real clinical practice with 
participation of numerous doctors in the treatment process, 
diagnostic procedures and surgery, that is more generaliz-
able than studies including only experts, and (iii) lack of 
specific time-dependent changes in diagnostics and proce-
dures associated with FDA restrictions. When thinking about 
developing the guidelines, it is important to concentrate 
on cheap and widely available diagnostic tools applicable 
in the case of typical gynecological symptoms as AUB. MRI 
was not considered as a diagnostic tool in the evaluation of 
women with benign diseases, as myomas or adenomyosis in 
our center, but probably it is performed in other healthcare 
systems where costs of diagnostics for obvious conditions 
are less limited.
A few other reports focused on LSH were published (Tab. 
8) [19–28]. Some studies have focused only on the incidence 
of occult leiomyosarcoma, because other malignancies, eg. 
EC, are considered easy to detect. However, the incidence 
of undetected morcellated EC may be higher, as was shown 
in another Polish study [27]. These incidents are a mater of 
financial compensation to the victims, especially in United 
States. Although the risk of EC may be higher [28], the ac-
cidents of undetected and morcellated cases are an issue 
of ongoing debates [29]. 
According to FDA statement power morcellators are 
contraindicated (i) for removal of tissue, which is known 
or suspected to contain malignancy, and (ii) in women 
Table. 8. Incidence of occult malignancy in studies focused on LSH
Study year Study years Total LSH, n Total uterine malignancy, n (%) EC, n (%) LMS, n (%) ESS, n (%) other 
Theben JU et al. [19] 2013 2005–2010 1584 4 (0.252) 2 (0.126) 2 (0.126) 0 0
Lieng M et al. [20] 2014 2000–2013 1846 1 (0.054) 0 1 (0.054) 0 0
Nugent W et al. [21] 2015 2004–2014 14 815 ? ? 16 (0.108) ? ?
Bojahr et al. [22] 2015 1998–2014 10 731 14 (0.13) 8 (0.075) 2 (0.019) 4 (0,037) 0
Brown J et al. [23] 2016 2002–2008 778 3 (0.386) 3 (0.386) 0 0 0
Rodriguez A et al. [24] 2016 2002–2011 12 226 ? ? 16 (0.131) ? ?
Perkins RB et al. [25] 2016 2007–2012 17 903 45 (0.251) ? ? ? 39 (0.218)
Vallabh-Patel DO et al. [26] 2016 2006–2015 786 4 (0.51) 4 (0.51) 0 0 0
Rechberger T et al. [27] 2016 2011–2015 426 4 (0.94) 3 (0.704) 0 0 1 (0.235)
von Bragen et al. [28] 2017 2007–2014 1044 6 5 0 1 0
Present study 2018 2010–2016 696 2 (0.29) 0 0 2 1 (0.14)
LSH — Laparoscopic supracervical hysterectomy; EC — Endometrial cancer; ESS — endometrial stromal sarcoma
473
Iwona Gawron et al., LSH and uterine malignancy
www. journals.viamedica.pl/ginekologia_polska
with myomas, who are (a) peri- or post-menopausal, or 
(b) candidates for en bloc tissue removal [30, 31]. Be-
cause, the most of women undergoing LSH with power 
morcellation may be a candidate for TLH, VH, and ab-
dominal hysterectomy or myomectomy with en bloc 
tissue removal, patients should be informed that LSH is 
not a baseline procedure, and may be associated with 
higher oncological risk than total hysterectomy. The re-
view of 27 studies from 2014–2016 performed by FDA 
indicates that laparoscopic morcellation of tissue with 
occult sarcoma is associated with lowering chances of 
long-term survival without cancer [31]. A hidden sarcoma 
may be present in 1/225 to 1/580, and leiomyosarcoma 
may be present in 1/495 to 1/1100 women undergoing 
myomas surgery without specification of the procedure 
type [30, 31].
In our cohort subjected to LSH no occult leiomyosar-
coma was found. Occult leiomyosarcoma in women with 
presumed myomas was the objective of a parallel study 
in our institution, with partially overlapping population, 
but focused only on women with myomas and the risk 
of occult leiomyosarcoma. The estimated incidence was 
similar to FDA’s previous and recent reports [18]. It should 
be noted that current research, focused on particular 
procedure (laparoscopy) and its explicit indications, 
might be a source of publication bias regarding the true 
prevalence of occult malignancies. However, to show 
results for LSH individually is justified in terms of raising 
patients’ and healthcare providers’ awareness of everyday 
practice [32]. It should be taken into consideration that 
in some situations it might be better to make a decision 
about complete hysterectomy (vaginal, laparoscopic or 
abdominal) than to insist on sparing the cervix. The sum-
marized data from all studies reporting occult uterine 
malignancies at LSH are depicted in Table 8. The most 
frequent occult malignancy was EC, eg. previous Polish 
study showed the incidence of EC equal to 1:142 [27]. 
No EC was encountered in our cohort, however 3 cases 
of AH were confirmed postoperatively. Including data 
from our study, the incidence of EC (given studies from 
Table 8, where EC cases specified) was 1:688 (0.15%). The 
incidence of all occult uterine malignancy (given stud-
ies from Table 8, including data from current study) was 
1:433 (0.23%) and in our study 1:348 (0.29%). Interest-
ingly, one histological specimen from our cohort of LSH 
revealed fallopian tube cancer. This fact should probably 
not be treated as complication but rather as an inciden-
tal finding, especially since it is difficult to assess what 
is better — to recognize the disease after morcellation 
with the risk of spreading malignancy or to diagnose the 
disease in advanced symptomatic stage during targeted 
treatment without morcellation.
Although morcellation of occult malignant tumor is con-
sidered to be an important complication of LSH, it should be 
noted that occult malignancy would have not been recog-
nized if the surgery had not been conducted. In conclusion, 
a consensus regarding obligatory diagnostic before LSH 
should be developed. If in a patient undergoing appropri-
ate diagnostics, including symptoms, imaging results and 
histopathological result from an endometrial biopsy (if nec-
essary), undetected malignant tumor will be morcellated, 
this should not be considered a professional misconduct, 
but rather as a possible adverse event. All patients should 
be informed about possibility of such event, and if they do 
not accept the risk (1/350), LSH should not be performed. 
Moreover, there are reasonable arguments that LSH should 
be performed in women, who do not agree to undergo 
total laparoscopic, vaginal and abdominal hysterectomy 
as baseline procedures. The boxed warning regarding: (i) 
the risk of unsuspected malignancy, (ii) the risk of spread of 
malignant cells, and (iii) and decrease the long-term survival 
of patients with unsuspected malignancy, who undergo 
LSH with power morcellation should be included to writ-
ten informed consent, similarly as is suggested by FDA for 
women with presumed myomas [31].
On the other hand, the risk of the spreading malignant 
cells may be lower if all practitioners use contained mor-
cellation [33]. Finally, it would be advisable to ultimately 
recommend the use of contained morcellation instead of 
open laparoscopic power morcellation.
CONCLUSIONS
A consensus regarding safe indications, required pre-op-
erative diagnostics, and justifiability of mandatory use of 
contained morcellation for LSH should be developed. When 
appropriate diagnostics is conducted, rare incidents of oc-
cult malignant tissue morcellation should not be consid-
ered as a professional misconduct but rather as possible 
adverse event. Patients should be informed about the risk 
of malignancy according to available estimations and that 
endometrial sampling cannot eliminate such a risk. 
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